FealtySign in

HCA Healthcare, Inc.

(HCA)

CIK 860730 · SEC filings only

Not gradedDividend record
shown as history
company entity
32 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

32 declarations · 8 raised · 21 held · 0 cut · held 21 quarters

  1. RAISED$0.7800/shperiod ended 2026-03-31Filing ↗
  2. HELD$0.7200/shperiod ended 2025-12-31Filing ↗
  3. HELD$0.7200/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.7200/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.7200/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.6600/shperiod ended 2024-12-31Filing ↗
  7. HELD$0.6600/shperiod ended 2024-09-30Filing ↗
  8. HELD$0.6600/shperiod ended 2024-06-30Filing ↗
  9. RAISED$0.6600/shperiod ended 2024-03-31Filing ↗
  10. HELD$0.6000/shperiod ended 2023-12-31Filing ↗
  11. HELD$0.6000/shperiod ended 2023-09-30Filing ↗
  12. HELD$0.6000/shperiod ended 2023-06-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
3 resolved promises

Not enough resolved promises to grade

3 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (2)

Open · buyback authorization

The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock.

resolves in ~132 days$10.0000receipt →
Open · buyback authorization

The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock.

resolves in ~500 days$10.0000receipt →

Credibility timeline

KEPT · Apr 27, 2023KEPT · May 1, 2025KEPT · Apr 29, 2026
20232026
Timeline as a list
  • Apr 27, 2023KEPTThe Board of Directors has also authorized a share repurchase program for up to an additional $6 billion of the Company’s outstanding common stock.
  • May 1, 2025KEPTThe HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $3 billion of the Company’s outstanding common stock.
  • Apr 29, 2026KEPTThe HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $6 billion of the Company’s outstanding common stock.
3 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
A+Guidance record
grade
company entity
5 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (19)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Jul 24, 2026
    $28.70 to $30.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Jul 14, 2026
    $28.70 to $30.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Jan 27, 2026
    EPS (diluted) $29.10 to $31.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Oct 24, 2025
    $27.00 to $28.00 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Jul 25, 2025
    $25.50 to $27.00 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Jan 24, 2025
    EPS (diluted) $24.05 to $25.85 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Jul 23, 2024
    $21.60 to $22.80 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Apr 26, 2024
    Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. $19.70 $21.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Jan 30, 2024
    EPS (diluted)  $19.70 to $21.20 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Oct 24, 2023
    Net income attributable to HCA Healthcare, Inc. $17.80 $18.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Apr 21, 2023
    $17.25 to $18.55 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Jan 27, 2023
    EPS (diluted) $16.40 to $17.60 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Apr 22, 2022
    EPS (diluted) $18.40 to $19.20 per diluted share $16.40 to $17.60 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Jan 27, 2022
    EPS (diluted) $18.40 to $19.20 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Oct 22, 2021
    EPS (diluted) $17.20 to $17.80 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Jul 20, 2021
    EPS (diluted) $16.30 to $17.10 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Apr 22, 2021
    $13.30 to $14.30 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Feb 2, 2021
    EPS (diluted) $12.10 to $13.10 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Jul 25, 2017
    EPS (diluted) $7.00 to $7.30 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (2) · 11 superseded

Open · revenue guidance fy

Revenues $43.0 to $44.0 billion

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

$77.000 to $79.500 billion

resolves in ~198 daysreceipt →
Superseded · revenue guidance fy

Revenues $72.80 to $75.80 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $60.0 to $62.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues  $67.75 to $70.25 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $57.0 to $58.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $53.5 to $55.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

$77.000 to $79.500 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

$74.00 to $76.00 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $61.5 to $63.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $54.0 to $55.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $67,750 $70,250

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $76.500 to $80.000 billion

revised by a later guidancereceipt →

Credibility timeline

KEPT · Feb 18, 2022KEPT · Feb 17, 2023BEAT · Feb 16, 2024KEPT · Feb 14, 2025KEPT · Feb 10, 2026
20222026
Timeline as a list
  • Feb 18, 2022KEPTRevenues $58.7 to $59.3 billion
  • Feb 17, 2023KEPTRevenues $60.0 to $62.0 billion $59.5 to $61.5 billion
  • Feb 16, 2024BEAT$62.5 to $64.5 billion
  • Feb 14, 2025KEPT$69.750 to $71.750 billion
  • Feb 10, 2026KEPT$75.000 to $76.500 billion
5 resolved guidance promises · 19dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →